NMD Pharma
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma - PIR International
Management — NMD Pharma
Thomas Holm Pedersen – CEO – NMD Pharma | LinkedIn
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Rare Neuromuscular Disease Company NMD Pharma Raises USD 3 Million in Seed Financing Round - Lundbeckfonden
Foundations invest DKK 280 million in biomedical company
Biopeople Newsletter January 2020 - Biopeople
NMD Pharma treats first patient with the firm's most promising drug candidate
Biotech completes financing round to advance neuromuscular treatments - EPM Magazine
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma treats first patient with the firm's most promising drug candidate
ALS Therapy Developer NMD Pharma Obtains $47 Million in New Financing
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma - Inkef capital
Prominent Canadian researcher in Denmark: Why I left a top job in California
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma - Inkef capital
NMD Pharma brænder 41 mio. kr. af sin kæmpeinvestering
Oct 23 | Neuromuscular Drug Development Summit (NMD) | Boston, MA Patch
NMD Pharma A/S | LinkedIn
Management — NMD Pharma
